Relationship Between Physical Activity and Mortality     

  The 2008 Physical Activity Guidelines for Americans recommended 150 to 300 minutes of moderate-intensity or 75 to 150 minutes of vigorous-intensity aerobic activity weekly for optimal health. However, these guidelines acknowledged uncertainty on the upper threshold of benefit or potential harms of high activity levels.  Using data from 6 pooled cohorts from the National Cancer Institute Cohort Consortium (baseline 1992-2003) […]

Read More…

Second-generation stents fail to BEST CABG

The technology of drug eluting stents for percutaneous coronary intervention (PCI) has improved over time with resultant improvements in patient outcomes.  Although prior studies have demonstrated the benefit of surgical coronary artery bypass grafting (CABG) over transcatheter PCI among patients with multivessel coronary artery disease (CAD), these studies did not incorporate newer generation drug-eluting stents.  […]

Read More…

Aspiration thrombectomy fails to demonstrate benefit in primary PCI  

Although primary percutaneous coronary intervention (PPCI) restores epicardial coronary flow in the majority of patients with ST-segment myocardial infarction, this approach can lead to microvascular obstruction resulting from distal embolization of thrombus.  Manual thrombectomy (i.e. aspiration thrombectomy) prior to PPCI has been proposed as a method to reduce thrombus burden and resultant distal embolization with […]

Read More…

Risk of adverse events changes over time following hospitalization

Readmissions and death after hospitalization are common.  However, there no data on how the risk for these adverse events changes over time following hospitalization.  In this study, the authors explored the absolute risk and changes in risk over time for readmission and mortality in the year following hospitalization for myocardial infarction (MI), pneumonia or heart […]

Read More…

Risks of NSAID Use after Myocardial Infarction

Nonsteroidal anti-inflammatory drugs (NSAID) are frequently used as over-the-counter and prescription medications.  Although prior studies have raised concern about the cardiovascular safety of these medications, detailed information on the risk of these medications in patients after myocardial infarction (MI) is lacking. In this study, retrospective Danish National Patient Registry data was evaluated for all patients […]

Read More…

HDL and Cardiovascular Risk: Rethinking the Relationship

Although lower HDL levels are associated with increased cardiovascular risk, therapies to raise HDL levels have failed to reduce cardiovascular events.  In this sub-study of the longitudinal Dallas Heart Study, the authors turn their attention from absolute levels of HDL to reverse cholesterol transport in the shape of HDL efflux capacity.  This efflux capacity is […]

Read More…

Surgical Repair of Moderate Mitral Regurgitation at the Time of CABG Lacks Clear Benefit

Ischemic mitral regurgitation (MR) is common and associated with poor outcomes among patients undergoing bypass surgery.  However, it remains unknown whether repair of ischemic MR concurrent to CABG leads to better patient outcomes.  To address this important clinical question, this multi-center study randomly assigned 301 patients with moderate ischemic MR to CABG alone or CABG […]

Read More…

The DENERHTN Randomized Controlled Trial: Renal Denervation for Resistant Hypertension Revisited

Despite large reductions in blood pressure seen in early studies of renal denervation, the SYMPLICITY HTN-3 randomized trial failed to show a reduction in systolic blood pressure with renal denervation when compared to medical therapy alone. As a result, interest in renal denervation as a treatment for resistant hypertension has waned.  In the DENERHTN trial, […]

Read More…

Coronary Artery Disease Screening Using CT Angiography Lacks Benefit

Although prior studies of screening for coronary artery disease (CAD) in high-risk patients have failed to demonstrate benefit, screening with cardiac coronary computed tomography (CCTA) may hold promise by providing more detail on the extent of coronary atherosclerosis.  This trial randomized 900 patients with a 3 to 5 years history of type 1 or 2 […]

Read More…

Why is Atherosclerotic Cardiovascular Disease Risk Overestimated by the ACC/AHA Pooled Cohort Equation?

The 2013 ACC/AHA Cholesterol Guidelines expand the recommendations for statin use to populations previously felt to be at lower risk. Central to risk-estimation in these guidelines is a new equation for determination of atherosclerotic cardiovascular disease (ASCVD) risk. However, this risk model has been criticized overestimating ASCVD risk in validation studies of the model.  Using […]

Read More…